A new Spherix Global Insights survey shows providers want administrative support for prior authorization while patients prioritize access and affordability
News|Articles|June 1, 2004
ACE inhibitor delays prevalence of WML in stroke victims
Perindopril, an angiotensin-converting enzyme (ACE) inhibitor, can help stop or delay the progress of white matter lesions (WML) in patients with prior cerebrovascular disease, according to research presented at the annual meeting of the American Academy of Neurology.
Advertisement
Advertisement
Related to this article
Pharmacy benefit managers are moving beyond formulary access to provide support programs for women's health. Here's how three PBMs — Judi Health, LucyRx and RxPreferred — are putting that strategy into practice.
Women face more gaps in healthcare than men, from missed screenings, undertreatment and biased coverage. PBMs are launching programs to address some of the gaps.
Navitus launched three modular options that let plan sponsors manage diabetes, weight, and lifestyle therapy access, cost, and outcomes with guaranteed ROI.
StarkRx has launched as a modular, cost-plus pharmacy benefit management company for self-funded employers using Judi Health’s PBM, Judi Rx, to administer claims.
A meta-analysis of 13 trials and 969 patients saw some short-term reductions in cancer-related pain and anxiety, especially during procedures, when using virtual reality.
Chad Hatfield, Pharm.D., M.H.A., BCPS, vice president and chief pharmacy officer of UC Davis Health, says pharmacists are embedded in “nearly all specialties," with more than 150 holding board certification.
8-year data show adjuvant Tagrisso boosts survival after surgery for EGFR-mutated NSCLC, reshaping early Lung Cancer care and adherence.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Alexis Sova, Pharm.D., MBA, on where GLP-1 coverage goes next | PBMI 2026
2
Alexis Sova, Pharm.D., MBA, on GLP-1 access when coverage ends | PBMI 2026
3
Systemic inflammation present even in mild hidradenitis suppurativa
4
Alexis Sova, Pharm.D., MBA, on employers pulling back on GLP-1 coverage | PBMI 2026
5